Vascularized composite allotransplantation: Towards tolerance and the importance of skin-specific immunobiology

Current Opinion in Organ Transplantation

Volumn 18, Issue 6, 2013, Pages 645-651

  Leonard, David A ^a   Kurtz, Josef M ^a,b   Cetrulo, Curtis L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b EMMANUEL COLLEGE   (United States)

Author keywords

Immunosuppression; Skin immunobiology; Tolerance; Transplant; Vascularized composite allotransplantation

Indexed keywords

RAPAMYCIN; TACROLIMUS;

ALLOTRANSPLANTATION; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); EFFECTOR CELL; GRAFT FAILURE; GRAFT REJECTION; HUMAN; IMMUNE DEFICIENCY; IMMUNOBIOLOGY; IMMUNOMODULATION; LANGERHANS CELL; MEMORY T LYMPHOCYTE; REGULATORY T LYMPHOCYTE; REVIEW; SKIN; SKIN ALLOGRAFT REJECTION; TRANSPLANTATION TOLERANCE; VASCULARIZED COMPOSITE ALLOTRANSPLANTATION;

GRAFT REJECTION; HUMANS; IMMUNE TOLERANCE; IMMUNOMODULATION; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; SKIN; T-LYMPHOCYTES; TRANSPLANTATION CHIMERA; TRANSPLANTATION, HOMOLOGOUS; VASCULARIZED COMPOSITE ALLOTRANSPLANTATION;

EID: 84888293513     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000022     Document Type: Review

References (51)

1. Petruzzo P, Lanzetta M, Dubernard JM, et al. The International Registry on Hand and Composite Tissue Transplantation. Transplantation 2010; 90:1590-1594.
2. Hautz T, Zelger BG, Weissenbacher A, et al. Standardizing skin biopsy sampling to assess rejection in vascularized composite allotransplantation. Clin Transplant 2013; 27:E81-E90.
3. Murray JE. Organ transplantation (skin, kidney, heart) and the plastic surgeon. Plast Reconstr Surg 1971; 47:425-431.
4. Medawar PB. The behaviour and fate of skin autografts and skin homografts in rabbits: a report to the War Wounds Committee of the Medical Research Council. J Anat 1944; 78:176-199.
5. Steinmuller D, Lofgreen JS. Differential survival of skin and heart allografts in radiation chimaeras provides further evidence for Sk histocompatibility antigen. Nature 1974; 248:796-797.
6. Steinmuller D, Tyler JD. Evidence of skin-specific alloantigens in cell-mediated cytotoxicity reactions. Transplant Proc 1980; 12:107-113.
7. Steinmuller D. The enigma of skin allograft rejection. Transplant Rev 1998; 12:42-57.
8. Bos JD, Zonneveld I, Das PK, et al. The skin immune system (SIS): distribution and immunophenotype of lymphocyte subpopulations in normal human skin. J Invest Dermatol 1987; 88:569-573.
9. Clark RA, Chong B, Mirchandani N, et al. The vast majority of CLA+ T cells are resident in normal skin. J Immunol 2006; 176:4431-4439.
10. Seneschal J, Clark RA, Gehad A, et al. Human epidermal Langerhans cells maintain immune homeostasis in skin by activating skin resident regulatory T cells. Immunity 2012; 36:873-884.
11. Chang J, Davis CL, Mathes DW. The impact of current immunosuppression strategies in renal transplantation on the field of reconstructive transplantation. J Reconstr Microsurg 2012; 28:7-19.
12. Schneeberger S, Landin L, Jableki J, et al. Achievements and challenges in composite tissue allotransplantation. Transpl Int 2011; 24:760-769.
13. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. U.S. Renal Data System, USRDS 2012 Annual Data Report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
14. Kaufman DB, Leventhal JR, Axelrod D, et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction: long-term results. Am J Transplant 2005; 5:2539-2548.
15. Unadkat JV, Schneeberger S, Horibe EH, et al. Composite tissue vasculopathy and degeneration following multiple episodes of acute rejection in reconstructive transplantation. Am J Transplant 2010; 10:251-261.
16. Sykes M, Sachs DH. Mixed chimerism. Philos Trans R Soc Lond B Biol Sci 2001; 356:707-726.
17. Sachs DH, Sykes M, Kawai T, et al. Immuno-intervention for the induction of transplantation tolerance through mixed chimerism. Semin Immunol 2011; 23:165-173.
18. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008; 358:353-361.
19. Leventhal J, Abecassis M, Miller J, et al. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med 2012; 4: 124ra28.
20. Kawai T, Cosimi AB, Colvin RB, et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 1995; 59:256-262.
21. Schwarze ML, Menard MT, Fuchimoto Y, et al. Mixed hematopoietic chimerism induces long-term tolerance to cardiac allografts in miniature swine. Ann Thorac Surg 2000; 70:131-138.
22. Horner BM, Cina RA, Wikiel KJ, et al. Predictors of organ allograft tolerance following hematopoietic cell transplantation. Am J Transplant 2006; 6:2894-2902.
23. Leonard DA, Cetrulo CL Jr, McGrouther DA, et al. Induction of tolerance of vascularized composite allografts. Transplantation 2013; 95:403-409.
24. Mathes DW, Hwang B, Graves SS, et al. Tolerance to vascularized composite allografts in canine mixed hematopoietic chimeras. Transplantation 2011; 92:1301-1308.
25. Hettiaratchy S, Melendy E, Randolph MA, et al. Tolerance to composite tissue allografts across a major histocompatibility barrier in miniature swine. Transplantation 2004; 77:514-521.
26. Kuo YR, Goto S, Shih HS, et al. Mesenchymal stem cells prolong composite tissue allotransplant survival in a swine model. Transplantation 2009; 87:1769-1777.
27. Leonard DA, Kurtz JM, Mallard C, et al. Vascularized composite allograft tolerance across MHCbarriers in a large animal model. Am J Transplant 2013; in press.
28. Wachtman GS, Wimmers EG, Gorantla VS, et al. Biologics and donor bone marrow cells for targeted immunomodulation in vascularized composite allotransplantation: a translational trial in swine. Transplant Proc 2011; 43:3541-3544.
29. Brandacher G, Lee WP, Schneeberger S. Minimizing immunosuppression in hand transplantation. Expert Rev Clin Immunol 2012; 8:673-683.
30. Schneeberger S, Gorantla VS, Brandacher G, et al. Upper-extremity transplantation using a cell-based protocol to minimize immunosuppression. Ann Surg 2013; 257:345-351.
31. Stingl G, Katz SI, Clement L, et al. Immunologic functions of Ia-bearing epidermal Langerhans cells. J Immunol 1978; 121:2005-2013.
32. Rubenfeld MR, Silverstone AE, Knowles DM, et al. Induction of lymphocyte differentiation by epidermal cultures. J Invest Dermatol 1981; 77:221-224.
33. Clark RA, Watanabe R, Teague JE, et al. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. Sci Transl Med 2012; 4:117ra7.
34. Jiang X, Clark RA, Liu L, et al. Skin infection generates nonmigratory memory CD8+ T(RM) cells providing global skin immunity. Nature 2012; 483:227-231.
35. Clark RA, Kupper TS. IL-15 and dermal fibroblasts induce proliferation of natural regulatory T cells isolated from human skin. Blood 2007; 109:194-202.
36. Clark RA, Huang SJ, Murphy GF, et al. Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J Exp Med 2008; 205:2221-2234.
37. Eljaafari A, Badet L, Kanitakis J, et al. Isolation of regulatory T cells in the skin of a human hand-allograft, up to six years posttransplantation. Transplantation 2006; 82:1764-1768.
38. Vukmanovic-Stejic M, Agius E, Booth N, et al. The kinetics of CD4+Foxp3+ T cell accumulation during a human cutaneous antigen-specific memory response in vivo. J Clin Invest 2008; 118:3639-3650.
39. Dudda JC, Perdue N, Bachtanian E, et al. Foxp3+ regulatory T cells maintain immune homeostasis in the skin. J Exp Med 2008; 205:1559-1565.
40. Tadokoro CE, Shakhar G, Shen S, et al. Regulatory T cells inhibit stable contacts between CD4+ T cells and dendritic cells in vivo. J Exp Med 2006; 203:505-511.
41. Egawa G, Kabashima K. Skin as a peripheral lymphoid organ: revisiting the concept of skin-associated lymphoid tissues. J Invest Dermatol 2011; 131:2178-2185.
42. Stary G, Klein I, Bauer W, et al. Glucocorticosteroids modify Langerhans cells to produce TGF-beta and expand regulatory T cells. J Immunol 2011; 186:103-112.
43. Merad M, Ginhoux F, Collin M. Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat Rev Immunol 2008; 8:935-947.
44. Kaplan DH, Jenison MC, Saeland S, et al. Epidermal Langerhans cell-deficient mice develop enhanced contact hypersensitivity. Immunity 2005; 23:611-620.
45. van der Aar AM, Picavet DI, Muller FJ, et al. Langerhans cells favor skin flora tolerance through limited presentation of bacterial antigens and induction of regulatory T cells. J Invest Dermatol 2013; 133:1240-1249.
46. + dermal dendritic cells at priming naive CD4(+) T cells. J Invest Dermatol 2010; 130:1345-1354.
47. Mathers AR, Janelsins BM, Rubin JP, et al. Differential capability of human cutaneous dendritic cell subsets to initiate Th17 responses. J Immunol 2009; 182:921-933.
48. Fujita H, Nograles KE, Kikuchi T, et al. Human Langerhans cells induce distinct IL-22-producing CD4+ T cells lacking IL-17 production. Proc Natl Acad Sci U S A 2009; 106:21795-21800.
49. Klechevsky E, Morita R, Liu M, et al. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 2008; 29:497-510.
50. Dunn TB, Noreen H, Gillingham K, et al. Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant 2011; 11:2132-2143.
51. Dubernard JM, Lengele B, Morelon E, et al. Outcomes 18 months after the first human partial face transplantation. N Engl J Med 2007; 357:2451-2460.